JP2019508429A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508429A5 JP2019508429A5 JP2018545198A JP2018545198A JP2019508429A5 JP 2019508429 A5 JP2019508429 A5 JP 2019508429A5 JP 2018545198 A JP2018545198 A JP 2018545198A JP 2018545198 A JP2018545198 A JP 2018545198A JP 2019508429 A5 JP2019508429 A5 JP 2019508429A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- ovarian cancer
- dna damage
- patient
- repair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022053212A JP2022079569A (ja) | 2016-02-29 | 2022-03-29 | 卵巣がんの処置のための併用療法 |
| JP2024019509A JP2024054312A (ja) | 2016-02-29 | 2024-02-13 | 卵巣がんの処置のための併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301225P | 2016-02-29 | 2016-02-29 | |
| US62/301,225 | 2016-02-29 | ||
| PCT/US2017/019843 WO2017151554A1 (en) | 2016-02-29 | 2017-02-28 | Combination therapy for treatment of ovarian cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022053212A Division JP2022079569A (ja) | 2016-02-29 | 2022-03-29 | 卵巣がんの処置のための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508429A JP2019508429A (ja) | 2019-03-28 |
| JP2019508429A5 true JP2019508429A5 (cg-RX-API-DMAC7.html) | 2020-04-09 |
Family
ID=59744380
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545198A Pending JP2019508429A (ja) | 2016-02-29 | 2017-02-28 | 卵巣がんの処置のための併用療法 |
| JP2022053212A Withdrawn JP2022079569A (ja) | 2016-02-29 | 2022-03-29 | 卵巣がんの処置のための併用療法 |
| JP2024019509A Pending JP2024054312A (ja) | 2016-02-29 | 2024-02-13 | 卵巣がんの処置のための併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022053212A Withdrawn JP2022079569A (ja) | 2016-02-29 | 2022-03-29 | 卵巣がんの処置のための併用療法 |
| JP2024019509A Pending JP2024054312A (ja) | 2016-02-29 | 2024-02-13 | 卵巣がんの処置のための併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11154538B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3423048A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2019508429A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108697666A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017227534A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3014680A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL261195B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018010223A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017151554A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| KR20200106053A (ko) * | 2017-12-29 | 2020-09-10 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 억제제를 사용한 암 치료 방법 |
| JP2021510702A (ja) | 2018-01-12 | 2021-04-30 | プロリンクス エルエルシー | 相乗的がん治療 |
| EP3966782A2 (en) | 2019-05-06 | 2022-03-16 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| CN113462784B (zh) * | 2021-08-31 | 2021-12-10 | 迈杰转化医学研究(苏州)有限公司 | 一种构建用于同源重组修复缺陷检测的靶标集合的方法 |
| JPWO2023157891A1 (cg-RX-API-DMAC7.html) | 2022-02-16 | 2023-08-24 | ||
| WO2024111564A1 (ja) * | 2022-11-21 | 2024-05-30 | 富士フイルム株式会社 | トポテカン又はその塩を内包するリポソーム組成物およびdna損傷修復阻害剤を含む組合せ医薬 |
| CN116024162B (zh) * | 2023-02-27 | 2025-01-10 | 山东大学 | Egcg联合chk2抑制剂在改善卵成熟或胚胎发育中的应用 |
| TW202502354A (zh) * | 2023-06-02 | 2025-01-16 | 美商薩諾管理公司 | 同源重組修復缺陷(hrd)作為預測性生物標記以便使用wee1抑制劑治療癌症 |
| CN117860753A (zh) * | 2023-11-30 | 2024-04-12 | 华中科技大学 | 一种cdc7抑制剂化合物xl413在制备预防或治疗肝损伤和肝纤维化药物及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2594874T3 (es) | 2004-11-18 | 2016-12-23 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad de HSP90 |
| AU2008321382A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| EP2714038A1 (en) * | 2011-05-24 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors |
| EP2714033A1 (en) * | 2011-05-26 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with chk inhibitors |
| WO2013067162A1 (en) * | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| WO2014138101A1 (en) | 2013-03-04 | 2014-09-12 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (hr) deficient cancer |
| JP6114075B2 (ja) * | 2013-03-07 | 2017-04-12 | 三菱航空機株式会社 | 航空機の警報システム、及び、航空機 |
| US20160120848A1 (en) * | 2013-05-21 | 2016-05-05 | Synta Pharmaceuticals Corp. | Specific cancer treatment regimes with ganetespib |
| DK3686288T3 (da) | 2014-08-15 | 2023-05-22 | Myriad Genetics Inc | Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens |
-
2017
- 2017-02-28 US US16/080,752 patent/US11154538B2/en not_active Expired - Fee Related
- 2017-02-28 CA CA3014680A patent/CA3014680A1/en active Pending
- 2017-02-28 JP JP2018545198A patent/JP2019508429A/ja active Pending
- 2017-02-28 WO PCT/US2017/019843 patent/WO2017151554A1/en not_active Ceased
- 2017-02-28 EP EP17760573.0A patent/EP3423048A4/en not_active Withdrawn
- 2017-02-28 AU AU2017227534A patent/AU2017227534A1/en not_active Abandoned
- 2017-02-28 CN CN201780013983.4A patent/CN108697666A/zh active Pending
- 2017-02-28 MX MX2018010223A patent/MX2018010223A/es unknown
-
2018
- 2018-08-16 IL IL261195A patent/IL261195B/en unknown
-
2022
- 2022-03-29 JP JP2022053212A patent/JP2022079569A/ja not_active Withdrawn
-
2023
- 2023-02-03 AU AU2023200554A patent/AU2023200554A1/en not_active Abandoned
-
2024
- 2024-02-13 JP JP2024019509A patent/JP2024054312A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Livraghi et al. | PARP inhibitors in the management of breast cancer: current data and future prospects | |
| Liu et al. | PARP inhibitors in ovarian cancer: current status and future promise | |
| Heitz et al. | Bevacizumab in the treatment of ovarian cancer | |
| Li et al. | Panax quinquefolium saponin attenuates cardiomyocyte apoptosis and opening of the mitochondrial permeability transition pore in a rat model of ischemia/reperfusion | |
| Molinaro et al. | Recent advances on pathophysiology, diagnostic and therapeutic insights in cardiac dysfunction induced by antineoplastic drugs | |
| Girek et al. | Novel tetrahydroacridine derivatives with iodobenzoic moieties induce G0/G1 cell cycle arrest and apoptosis in A549 non-small lung cancer and HT-29 colorectal cancer cells | |
| JP2023175694A (ja) | 2,4,6-トリフルオロ-n-[6-(1-メチル-ピペリジン-4-カルボニル)-ピリジン-2-イル]-ベンズアミドの組成物 | |
| Slator et al. | Triggering autophagic cell death with a di-manganese (II) developmental therapeutic | |
| JP2021510702A5 (cg-RX-API-DMAC7.html) | ||
| Guo et al. | Pyroptosis in glioma: current management and future application | |
| JP2019508429A (ja) | 卵巣がんの処置のための併用療法 | |
| Hu et al. | Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice | |
| Payne et al. | DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial | |
| Musella et al. | PARP inhibition: A promising therapeutic target in ovarian cancer | |
| Pillai et al. | PL03. 09: phase 3 study of ganetespib, a heat shock protein 90 inhibitor, with Docetaxel versus Docetaxel in advanced non-small cell lung cancer (GALAXY-2) | |
| Murai et al. | Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition | |
| Kruse et al. | PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy | |
| US20140120182A1 (en) | Method for the treatment of cancer | |
| US20250270268A1 (en) | Amelioration and treatment of infarction damage | |
| Moro-Sibilot et al. | Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study) | |
| Ren et al. | NCOA4-mediated ferritinophagy promotes pyroptosis by reactive oxygen species generation in the progress of gingival inflammation | |
| Alharbi et al. | DOX and MET treatment induces cognitive impairment through downregulation of IL-1-alpha and IRS-1 in the rat brain. | |
| Abolhoda et al. | Morbidity and mortality for pulmonary resections in lung cancer after induction treatment | |
| Reck et al. | Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma | |
| AR077189A1 (es) | Comprimidos de ibuprofeno de sodio y procedimiento de fabricacion de composiciones farmaceuticas que incluyen ibuprofeno de sodio |